January 2024: Funding
Ceria Therapeutics, Inc. Awarded a $2,000,000 SBIR Grant to Advance Development of a Novel Treatment for Non-healing Diabetic Foot Ulcers
October 2023: Funding
Ceria Therapeutics, Inc. Awarded a $3,800,000 DoD Contract to Advance Development of a Novel Treatment for Acute Lung Injuries
September 2023: Funding
Ceria Therapeutics, Inc. Awarded a $2,100,000 SBIR Grant to Advance Development of a Novel Treatment for Acute Lung Injuries, Acute Lung Failure, and Acute Respiratory Distress Syndrome
September 2022: Funding
Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers
February 2022: Publication
Photopolymerized Zwitterionic Hydrogels with a Sustained Delivery of Cerium Oxide Nanoparticle-miR146a Conjugate Accelerate Diabetic Wound Healing
May 2021: Funding
$8.6 million Advanced Industries Awards Accelerate 36 Colorado Start-ups:
Ceria Therapeutics, Inc. – Aurora, CO $250,000 – CTx is developing a pipeline of drug products based on a single active agent to treat inflammatory diseases with severe morbidity such as nonhealing wounds, acute lung inflammation and severe intestinal distress. The company’s core technology addresses these conditions with single-administration drug products that block the underlying cause to rapidly resolve each condition. Patient benefits include the prevention of long-term drug therapy, surgery and even death.
November 2021: Publication
Lung function improves after delayed treatment with CNP-miR146a following acute lung injury
November 2021: Publication
Cerium oxide nanoparticle conjugation to microRNA-146a mechanism of correction for impaired diabetic wound healing
June 2021: Publication
Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury
October 2020: Publication
Nanosilk Increases the Strength of Diabetic Skin and Delivers CNP-miR146a to Improve Wound Healing
August 2020: FDA Feedback for the ARDS Application
PRE-IND feedback received from FDA for COVID-19 positive ARDS indication
July 2020: FDA CTAP
FDA grants CTAP (Coronavirus Treatment Acceleration Program) designation for COVID-19 Positive ARDS Pre-IND
March 2020: Investment
Early Investment by Children’s Hospital CO
Jan 2020: Publication
Injectable, self-healable zwitterionic cryogels with sustained microRNA – cerium oxide nanoparticle release promote accelerated wound healing
November 2019
Ceria Therapeutics was founded
August 2019: FDA Feedback for the DFU Application
FDA feedback on DFU pre-IND
Jan 2019: Publication
Use of Cerium Oxide Nanoparticles Conjugated with MicroRNA-146a to Correct the Diabetic Wound Healing Impairment